NCT02905318View on ClinicalTrials.gov

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

April 29, 2022

Study Completion Date

December 30, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Palbociclib

125 mg orally on days 1-21 each 28 day cycle

Trial Locations (7)

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK